FCM
BIIB icon

Fourpath Capital Management’s Biogen BIIB Stock Holding History

Fourpath Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-648
Closed -$126K – 291
2024
Q3 		$126K Sell
648
-281
-30% -$58.8K 0.02% 259
2024
Q2 		$215K Sell
929
-106
-10% -$23K 0.16% 122
2024
Q1 		$223K Sell
1,035
-53
-5% -$12.4K 0.15% 128
2023
Q4 		$282K Sell
1,088
-15
-1% -$3.68K 0.19% 97
2023
Q3 		$283K Sell
1,103
-29
-3% -$7.76K 0.21% 94
2023
Q2 		$322K Sell
1,132
-20
-2% -$5.95K 0.39% 70
2023
Q1 		$320K Buy
1,152
+1
+0.1% +$277 0.22% 97
2022
Q4 		$319K Sell
1,151
-221
-16% -$62.4K 0.23% 90
2022
Q3 		$366K Sell
1,372
-272
-17% -$57.8K 0.25% 80
2022
Q2 		$335K Sell
1,644
-288
-15% -$58.9K 0.21% 101
2022
Q1 		$407K Sell
1,932
-1
-0.1% -$217 0.16% 106
2021
Q4 		$464K Buy
+1,933
New +$497K 0.18% 98

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fourpath Capital Management's BIIB Position: Q4 2024 in Review

Fourpath Capital Management sold out of Biogen (BIIB) in Q4 2024, closing a stake of 648 shares — an estimated $126K sold.

Fourpath Capital Management first reported a position in BIIB in Q4 2021 and held it in 12 quarters. The position peaked at $464K in Q4 2021. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

  • Fourpath Capital Management reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 648 Biogen shares in Q4 2024, an estimated $126K.
  • Fourpath Capital Management first reported a position in Biogen in Q4 2021 and held it in 12 quarters.
  • Fourpath Capital Management's Biogen position peaked at $464K in Q4 2021.
  • 876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.